

3033 US0P

Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Complete if Known Substitute for form 1449/PTO Application Number -Based on PCT/JP03/02783 Filing Date Intl. Filing 10 MARCH 2003 INFORMATION DISCLOSURE First Named Inventor HARA, Takahito STATEMENT BY APPLICANT Art Unit tba (Use as many sheets as necessary) **Examiner Name** tba

Attorney Docket Number

Examiner	Cite	Document Number	Publication Date	Name of Patentee or	Pages Columns Lines Mines
Initials*	Cite No.1	Number-Kind Code ^{2 (# trown)}	MM-DD-YYYY	Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
/MMC	A 1	^{US-} 4,472,382	09/18/1984	F. Labrie, et al.	
		US-			
-		US-			
		US-			
		US-			
		US-	<u> </u>		
		US-			
		US-			

		FORE	IGN PATENT DOCU	JMENTS		
Examiner Initials*	Cite No.1	Foreign Patent Document	Publication Date	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages	T
		Country Code ³ Number ⁴ 'Kind Code ⁸ (# known)	MM-DD-YYYY		Or Relevant Figures Appear	T⁰
/MMCG	/ A2	WO 90/10462	09/20/1990	Endorecherche Inc.		V
W/	А3	EP 0413209 A1	02/20/1991	Abbott Laboratories		V
V	A4	WO 96/40150	12/19/1996	Merck & Co., Inc.		~
/MMC0	/A5	WO 00/57892-Abstract only	10/05/2000	Pierre Fabre Medicament		
	i					

Examiner		Date	
Signature	/Marcela M Cordero Garcia/	Considered	03/14/2007

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 'Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached.

Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the Individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

PTO/SB/08B (08-03)
Approved for use through 07/31/2008. OMB 0651-0031
U.S. Patent and Tradamark Office; U.S. DEPARTMENT OF COMMERCE

Substitute for form 1449/PTO				Complete if Known		
				Application Number	Based on PCT/JP03/02783	
INF	ORMATION	DIS	CLOSURE	Filing Date	Intl. Filing 10 MARCH 2003	
STATEMENT BY APPLICANT			PPLICANT	First Named Inventor	HARA, Takahito	
(Use as many sheets as necessary)				Art Unit	tba	
(Use as many sheets as notossary)			ocossa/y)	Examiner Name	tba	
Sheet	2	of	2	Attorney Docket Number	3033 US0P	

		NON PATENT LITERATURE DOCUMENTS	
Examiner Initials*	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
/MMCG/	A6	J. KOKONTIS, et al., "Increased Androgen Receptor Activity and Altered c-myc Expression in Prostate Cancer Cells after Long-Term Androgen Deprivation", Cancer Res., (1994), pp. 1566-1573, Vol. 54.	~
/MMC0	6/ _{A7}	Y. UMEKITA, et al., "Human Prostate Tumor Growth in Athymic Mice: Inhibition by Androgens and Stimulation by Finasteride", Proc. Natl. Acad. Sci. USA, (1996), pp. 11802-11807, Vol. 93.	8
·			

			
Examiner	Managla M. Candana Canaial	Date	00/44/0007
C:	/Marcela M Cordero Garcia/	1 2	03/14/2007
Signature		Considered	00/11/2001

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.